BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines 2014;13:221-34. [PMID: 24308581 DOI: 10.1586/14760584.2014.864563] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis 2015;15:389. [PMID: 26404632 DOI: 10.1186/s12879-015-1112-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
2 Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 2018;17:739-51. [PMID: 30056767 DOI: 10.1080/14760584.2018.1506333] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
3 Thompson KM, Kalkowska DA. Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Anal 2021;41:349-63. [PMID: 32645244 DOI: 10.1111/risa.13557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology 2016;11:1549-61. [DOI: 10.2217/fmb-2016-0126] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
5 Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine 2015;33:1235-42. [PMID: 25600519 DOI: 10.1016/j.vaccine.2015.01.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
6 Thompson KM. Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. Lancet 2014;384:1480-2. [PMID: 25018123 DOI: 10.1016/S0140-6736(14)60983-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis 2015;15:379. [PMID: 26382043 DOI: 10.1186/s12879-015-1115-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
8 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Risk Anal 2021;41:248-65. [PMID: 31960533 DOI: 10.1111/risa.13447] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
10 Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014;210 Suppl 1:S485-97. [PMID: 25316871 DOI: 10.1093/infdis/jit838] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
11 Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. Epidemiol Infect 2017;145:217-26. [PMID: 27760579 DOI: 10.1017/S0950268816002302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
12 Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. Expert Review of Vaccines 2017;16:577-86. [DOI: 10.1080/14760584.2017.1322514] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
13 Tebbens RJD, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. Syst Dyn Rev 2018;34:78-120. [PMID: 34552305 DOI: 10.1002/sdr.1589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kalkowska DA, Thompson KM. Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria. Risk Anal 2021;41:303-11. [PMID: 32348634 DOI: 10.1111/risa.13486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Thompson KM, Duintjer Tebbens RJ. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes. J Infect Dis 2017;216:S168-75. [PMID: 28838198 DOI: 10.1093/infdis/jix128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
16 Thompson KM, Kalkowska DA. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Anal 2021;41:229-47. [PMID: 32339327 DOI: 10.1111/risa.13484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
17 Duintjer Tebbens RJ, Thompson KM. Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use. MDM Policy Pract 2017;2:2381468317697002. [PMID: 30288417 DOI: 10.1177/2381468317697002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
18 Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Rev Vaccines 2019;18:725-36. [PMID: 31248293 DOI: 10.1080/14760584.2019.1635463] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
19 Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One 2015;10:e0130123. [PMID: 26068928 DOI: 10.1371/journal.pone.0130123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
20 Koopman JS, Henry CJ, Park JH, Eisenberg MC, Ionides EL, Eisenberg JN. Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped. Epidemics 2017;20:21-36. [PMID: 28283373 DOI: 10.1016/j.epidem.2017.02.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
21 Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis 2015;15:374. [PMID: 26381878 DOI: 10.1186/s12879-015-1113-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
22 Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. J Vaccines Vaccin 2016;7:340. [PMID: 28690915 DOI: 10.4172/2157-7560.1000340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 0.2] [Reference Citation Analysis]
23 Thompson KM, Duintjer Tebbens RJ. Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples. Risk Anal 2016;36:1487-509. [PMID: 25109229 DOI: 10.1111/risa.12265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect 2019;147:e295. [PMID: 31647050 DOI: 10.1017/S095026881900181X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
25 Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D. Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine. PLoS Pathog 2016;12:e1005483. [PMID: 27032093 DOI: 10.1371/journal.ppat.1005483] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
26 Thompson KM. Modeling and Managing Poliovirus Risks: We are Where we are…. Risk Anal 2021;41:223-8. [PMID: 33590520 DOI: 10.1111/risa.13668] [Reference Citation Analysis]
27 Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine 2015;33:1568-77. [PMID: 25701673 DOI: 10.1016/j.vaccine.2015.02.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
28 Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines 2021;20:449-60. [PMID: 33599178 DOI: 10.1080/14760584.2021.1891889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. J Infect Dis 2014;210 Suppl 1:S398-411. [PMID: 25316861 DOI: 10.1093/infdis/jit844] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
30 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations. Risk Anal 2018;38:1701-17. [PMID: 29314143 DOI: 10.1111/risa.12962] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
31 Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines 2020;19:661-86. [PMID: 32741232 DOI: 10.1080/14760584.2020.1791093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
32 Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014;210 Suppl 1:S475-84. [PMID: 25316870 DOI: 10.1093/infdis/jit845] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
33 Venkatesan MM, Van de Verg LL. Combination vaccines against diarrheal diseases. Hum Vaccin Immunother 2015;11:1434-48. [PMID: 25891647 DOI: 10.4161/21645515.2014.986984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]